NASDAQ:FLKS Flex Pharma (FLKS) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free FLKS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.48▼$0.5150-Day Range$0.57▼$14.5152-Week Range$0.26▼$1.49Volume3,710 shsAverage Volume2.03 million shsMarket Capitalization$9.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Flex Pharma alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Flex Pharma Stock (NASDAQ:FLKS)Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.Read More Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. FLKS Stock News HeadlinesApril 4, 2024 | seekingalpha.comFlex Ltd.: Undervalued With Solid FundamentalsNovember 17, 2023 | seekingalpha.comFLEX LNG Ltd. 2023 Q3 - Results - Earnings Call PresentationApril 26, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.October 30, 2023 | msn.comUnforgettable Patients: A guy came to the ER for a scratch on his neck and "feeling drowsy." As we start the routine workups, he suddenly drops dead. Days later, his autopsy ...September 4, 2023 | msn.comANGLE release Portrait Flex CTC assaySeptember 1, 2023 | msn.comWhy flex work is as important as pay for someJune 3, 2023 | news.yahoo.com22-year-old woman arrested in Forks after threatening homeowner with gunMay 24, 2023 | fool.comFlex (NASDAQ: FLEX)April 26, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!March 28, 2023 | wsj.comFlex Ltd.March 25, 2023 | forbes.comThat's All Folks: Why the Writing Is on the Wall at MicrosoftMarch 24, 2023 | bbc.co.ukFolk Club with Lynette FayMarch 10, 2023 | msn.comCalifornia flexed its muscle on abortion rights. Will more states and businesses follow?December 12, 2022 | news.yahoo.comCompany to add new flex work space to ShelbySeptember 7, 2022 | finance.yahoo.comOptimal Flex Plays: We are back baby!August 11, 2022 | seekingalpha.comOncoCyte Corporation (OCX) CEO Ronnie Andrews on Q2 2022 Results - Earnings Call TranscriptJune 16, 2022 | seekingalpha.comThe Kraft Heinz Company's (KHC) Management Presents at Deutsche Bank Annual dbAccess Global Consumer Conference (Transcript)June 15, 2022 | seekingalpha.comThe Kraft Heinz Company (KHC) Presents at Deutsche Bank Annual dbAccess Global Consumer Conference (Transcript)June 8, 2022 | finance.yahoo.comOver 500+ Weight Loss Smoothie Recipes Revealed By Cocinaré For Their New Gopower eLite Personal Portable Blender LaunchMay 21, 2022 | dailymail.co.ukMonkeypox is now spotted in Italy and Sweden — bringing number of countries with confirmed or suspected cases to SEVENMay 20, 2022 | msn.comMy Fair Lady, The Breach and Rambert: The best of the week’s live reviewsMay 16, 2022 | seekingalpha.comGinkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q1 2022 Results - Earnings Call TranscriptMay 14, 2022 | seekingalpha.comZymergen, Inc. (ZY) CEO Jay Flatley on Q1 2022 Results - Earnings Call TranscriptMay 5, 2022 | seekingalpha.comBecton, Dickinson and Company (BDX) CEO Thomas Polen on Q2 2022 Results - Earnings Call TranscriptApril 14, 2022 | ca.finance.yahoo.comToyota's first EV will start at $42,000March 6, 2022 | yahoo.comBiden May Extend Pause On Student Loan Payments Again: Top AideJanuary 31, 2022 | msn.comFord F-150, Chevy Silverado, Ram 3500 Flex Some Muscle In Tug Of WarSee More Headlines Receive FLKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Flex Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FLKS CUSIPN/A CIK1615219 Webwww.flex-pharma.com Phone617-874-1821FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,920,000.00 Net Margins-1,208.42% Pretax MarginN/A Return on Equity-98.04% Return on Assets-83.37% Debt Debt-to-Equity RatioN/A Current Ratio6.86 Quick Ratio6.74 Sales & Book Value Annual Sales$840,000.00 Price / Sales10.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book0.98Miscellaneous Outstanding Shares18,070,000Free FloatN/AMarket Cap$9.02 million OptionableNot Optionable Beta1.65 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. William K. McVicar (Age 61)Pres, CEO & Director Dr. Roderick MacKinnon (Age 63)Co-Founder & Co-Chair of Scientific Advisory Board Mr. John McCabe (Age 49)CFO, Treasurer & Sec. Dr. Thomas C. Wessel (Age 63)Outside Advisor Dr. Bruce BeanCo-Founder, Co-Chair of Scientific Advisory Board & Board ObserverKey CompetitorsAeterna ZentarisNASDAQ:AEZSAkari TherapeuticsNASDAQ:AKTXNuCanaNASDAQ:NCNAMolecular TemplatesNASDAQ:MTEMVirios TherapeuticsNASDAQ:VIRIView All Competitors FLKS Stock Analysis - Frequently Asked Questions How were Flex Pharma's earnings last quarter? Flex Pharma Inc (NASDAQ:FLKS) posted its quarterly earnings results on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company had revenue of $0.11 million for the quarter. Flex Pharma had a negative trailing twelve-month return on equity of 98.04% and a negative net margin of 1,208.42%. What other stocks do shareholders of Flex Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flex Pharma investors own include Ocular Therapeutix (OCUL), Micron Technology (MU), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), Gilead Sciences (GILD), Histogenics (HSGX), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Celldex Therapeutics (CLDX) and Melinta Therapeutics (MLNT). When did Flex Pharma IPO? Flex Pharma (FLKS) raised $60 million in an IPO on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers. This page (NASDAQ:FLKS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
